A Fabry disease genetic test looks for disease-causing variants in the GLA gene, which provides instructions for the lysosomal enzyme alpha-galactosidase A. When this enzyme does not work well enough, certain fatty substances—especially globotriaosylceramide and related compounds—can build up in cells throughout the body. The effects may involve nerves, skin, kidneys, heart, brain, hearing, eyes, and digestion. Testing is especially important because Fabry disease can look very different from one person to another. Some males develop pain and sweating problems in childhood, while others first present with heart or kidney disease decades later. Females with a GLA variant are not simply unaffected carriers; they may have mild, severe, or late-onset organ disease. Diagnosis usually combines GLA analysis with alpha-galactosidase A enzyme activity, the biomarker lyso-Gb3, family history, and organ evaluation. A pathogenic result can guide treatment eligibility, surveillance, and testing of relatives, but an uncertain variant requires careful evidence before it is labeled Fabry disease.
- A pathogenic or likely pathogenic GLA variant can confirm Fabry disease, but the clinical effect depends on sex chromosomes, variant type, enzyme function, age, and other factors.
- Very low alpha-galactosidase A activity strongly supports Fabry disease in males, while normal enzyme activity does not rule it out in females.
- Lyso-Gb3 can support diagnosis and monitoring, but a normal value—especially in a female or late-onset case—does not exclude Fabry disease.
- GLA testing should usually include sequencing plus deletion-and-duplication analysis when initial sequencing is negative and suspicion remains.
- A variant of uncertain significance does not confirm Fabry disease and should not be used alone to begin lifelong disease-specific treatment.
- Sudden stroke symptoms, fainting, severe chest pain, or major breathing difficulty require urgent care, whether or not Fabry disease has been fully confirmed.
Table of Contents
- Why GLA Testing Is Ordered
- Classic and Late-Onset Fabry Disease
- The Diagnostic Testing Pathway
- GLA Laboratory Methods
- How to Interpret GLA Results
- Organ Evaluation and Treatment Relevance
- X-Linked Inheritance and Family Testing
- Unresolved Results and Next Steps
Why GLA Testing Is Ordered
GLA testing is ordered when symptoms, organ findings, newborn screening, or family history suggest Fabry disease. The condition is a lysosomal storage disorder: alpha-galactosidase A normally helps break down specific glycosphingolipids inside lysosomes, the cell’s recycling compartments. Reduced enzyme activity allows these substances and their derivatives to accumulate and contribute to cell injury.
Fabry disease can be missed because no single symptom appears in everyone. Early clues may seem unrelated and may be treated separately for years. Testing may be considered in a person with several of the following findings:
- Burning or stabbing pain in the hands and feet, often triggered by heat, fever, exercise, stress, or temperature change
- Reduced sweating, excessive sweating, or poor heat tolerance
- Clusters of dark red or purple skin spots called angiokeratomas
- Cornea verticillata, a whorl-like corneal pattern found during an eye examination
- Recurrent abdominal pain, diarrhea, nausea, early fullness, or other unexplained gastrointestinal symptoms
- Protein or albumin in the urine, declining kidney function, or kidney failure without a clear cause
- Thickening of the heart muscle, unexplained left ventricular hypertrophy, arrhythmia, conduction disease, or heart failure
- Stroke or transient ischemic attack at an unusually young age
- Tinnitus, hearing loss, dizziness, or sudden hearing changes
- A relative with a GLA variant, Fabry disease, unexplained early kidney failure, cardiomyopathy, or stroke
Some people are identified through high-risk screening programs in cardiology, nephrology, dialysis, stroke, or newborn settings. A screening result is not always a final diagnosis. Low enzyme activity from a dried blood spot may need confirmation in plasma or leukocytes, and a detected GLA variant may require expert classification.
Testing is also used for relatives after a familial pathogenic variant has been established. Targeted testing for the exact family variant is usually faster and clearer than repeating broad sequencing in every relative.
Classic and Late-Onset Fabry Disease
Fabry disease forms a spectrum rather than two perfectly separated categories. Still, the terms classic and late-onset help describe common patterns.
Classic Fabry disease usually begins in childhood or adolescence, especially in males with very little alpha-galactosidase A activity. Early manifestations may include pain crises, heat and exercise intolerance, sweating abnormalities, angiokeratomas, gastrointestinal symptoms, corneal changes, and early protein in the urine. Without effective management, progressive kidney, cardiac, and cerebrovascular disease can develop later.
Late-onset Fabry disease may first appear in adulthood and can mainly affect one organ system. A person may have hypertrophic cardiomyopathy, arrhythmia, kidney disease, or stroke without the classic childhood pain, skin lesions, or sweating problems. Some late-onset variants leave more residual enzyme activity than classic variants, but an enzyme percentage alone cannot define the full phenotype.
The presentation also differs between people with one X chromosome and those with two. A male with one pathogenic GLA variant has no second GLA copy to compensate and is described as hemizygous. Classic males often have markedly deficient enzyme activity; GeneReviews describes classic disease as usually having less than 1% of normal alpha-galactosidase A activity.
A female with one pathogenic GLA variant is heterozygous. Because one X chromosome is largely inactivated in each cell, the proportion of cells using the altered or normal GLA copy can vary among tissues. This process helps explain why some females remain mildly affected while others develop substantial heart, kidney, neurologic, pain, or hearing disease. Blood enzyme activity may be normal even when clinically important Fabry disease is present.
The terms “carrier” and “affected” therefore need care. A heterozygous female may transmit the variant and may also require her own surveillance and treatment. Dismissing symptoms because she is “only a carrier” can delay diagnosis.
Genotype can suggest a broad pattern, but it rarely predicts an exact course. Even relatives with the same variant can differ in age of onset, affected organs, and severity. A report should not promise that a person will remain heart-only, kidney-only, mild, or symptom-free.
The Diagnostic Testing Pathway
Fabry diagnosis is strongest when genetics, enzyme testing, biomarkers, symptoms, and organ findings agree. The sequence of testing differs by sex, age, clinical setting, and whether a family variant is already known.
Alpha-galactosidase A enzyme activity
In males, measuring alpha-galactosidase A activity in plasma, leukocytes, or cultured cells is an efficient first step. Markedly low activity strongly supports Fabry disease, and GLA testing then identifies the molecular cause. Testing both plasma and leukocytes may be useful because some variants affect enzyme secretion or trafficking differently.
In females, enzyme activity is not a reliable exclusion test. A low result can support the diagnosis, but a normal result cannot rule it out. Direct GLA genetic testing is therefore central when Fabry disease is suspected in a female.
Dried blood spot enzyme testing is convenient for screening and sample transport, but abnormal results usually need confirmation. Heat, humidity, delayed transport, poor specimen quality, or laboratory cutoffs can affect screening measurements.
Lyso-Gb3
Globotriaosylsphingosine, usually called lyso-Gb3, is a blood biomarker related to the stored substances in Fabry disease. It is often substantially elevated in classic males and can support diagnosis, phenotype assessment, and treatment monitoring.
Lyso-Gb3 is not a stand-alone yes-or-no test. Values vary by laboratory method, sex, phenotype, age, kidney function, treatment, and variant. Late-onset males may have modest elevations, and some heterozygous females have values within or near the reference range. A normal lyso-Gb3 result should not override a pathogenic GLA variant or a strong clinical picture.
Serial results are most useful when measured by the same laboratory and interpreted with organ outcomes. A decrease after treatment can show a biochemical response, but it does not guarantee that established heart fibrosis, kidney scarring, pain, or stroke risk has reversed.
Clinical and organ assessment
A molecular result does not replace examination of the organs Fabry disease can affect. Initial evaluation may include:
- Urine albumin or protein measurement, serum creatinine, and estimated glomerular filtration rate
- Electrocardiogram, echocardiogram, rhythm monitoring, and cardiac magnetic resonance imaging when appropriate
- Neurologic history and brain imaging based on age, symptoms, and specialist recommendations
- Hearing assessment
- Eye examination for corneal and lenticular changes
- Skin, pain, sweating, gastrointestinal, pulmonary, and mental health review
Kidney or heart biopsy is not required for most genetically clear cases, but tissue findings may help when a variant is uncertain and organ disease has several possible causes. Biopsy interpretation should account for medications and other conditions that can produce storage-like changes.
GLA Laboratory Methods
GLA testing usually begins with sequence analysis. The laboratory reads the coding exons and nearby splice junctions to detect single-nucleotide variants and small insertions or deletions. These include missense variants that change one amino acid, nonsense variants that create an early stop signal, splice variants that alter RNA processing, and small frameshift variants.
If sequencing does not find a pathogenic variant and suspicion remains, deletion-and-duplication analysis can look for loss or gain of one or more exons or the entire gene. Routine sequencing may not reliably detect these copy-number changes.
A complete report should identify:
- The GLA transcript used for naming the variant
- The DNA and protein-level variant description
- The classification and evidence summary
- The assay’s coverage and detection limits
- Whether deletion-and-duplication analysis was performed
- Whether the variant is considered amenable to a pharmacologic chaperone under an accepted assay or regional product information
- Recommendations for confirmation, family testing, or clinical correlation
Some pathogenic changes lie outside standard coding regions and may affect splicing or gene regulation. RNA analysis can help evaluate selected intronic or splice-region variants. In unresolved cases, genome sequencing or research testing may be considered, but these approaches are not substitutes for careful review of standard assay coverage.
Mosaicism is uncommon but possible. A mosaic person has the variant in some cells rather than all cells, which can lower the variant fraction detected in blood. Deep sequencing or another tissue may be needed if the clinical findings are convincing but the blood result is borderline or inconsistent.
Testing laboratories may disagree about a variant because they use different evidence, databases, or dates of review. The exact variant and evidence matter more than a generic statement that the test was “positive.”
How to Interpret GLA Results
GLA variants are generally classified as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. The category describes confidence that the variant causes disease, not the severity of disease in one person.
| Result | Usual interpretation | Next step |
|---|---|---|
| Pathogenic or likely pathogenic variant | Confirms or strongly supports Fabry disease when the result is technically sound. | Complete organ assessment, review treatment eligibility, and offer targeted family testing. |
| Variant of uncertain significance | Evidence is insufficient or conflicting; Fabry disease is not confirmed by the variant alone. | Compare enzyme activity, lyso-Gb3, phenotype, family segregation, databases, and functional evidence. |
| Negative sequence result | No reportable variant was found in the regions tested. | Review clinical likelihood, enzyme results, deletion-and-duplication testing, and alternative diagnoses. |
| Benign or likely benign variant | The change is not considered a cause of Fabry disease. | Do not base Fabry-specific treatment or family risk on that variant. |
| Indeterminate or conflicting result | The assay or interpretation did not resolve the finding. | Seek review from a Fabry-experienced genetics or metabolic center. |
A pathogenic result in a male with very low enzyme activity and compatible symptoms is usually straightforward. A pathogenic result in a female also establishes the genetic diagnosis, even if enzyme activity is normal. Her current organ involvement must then be assessed rather than assumed from the laboratory result.
Missense variants need particular care because some reduce enzyme function severely, some cause later-onset disease, and some are benign or have disputed significance. Low enzyme activity in a screening assay does not prove that every detected missense change causes Fabry disease. Some variants can produce pseudodeficiency or altered laboratory activity without the progressive multisystem disease expected in Fabry disease.
A VUS should not be converted into a diagnosis merely because the person has a common finding such as left ventricular hypertrophy or kidney disease. Stronger evidence may come from markedly low enzyme activity in a male, elevated lyso-Gb3, characteristic tissue storage, a consistent family pattern, RNA studies, validated functional assays, or later reclassification.
Conversely, a normal lyso-Gb3 value or mild symptoms should not erase a well-established pathogenic GLA variant. The right interpretation uses all available evidence without allowing one test to dominate inappropriately.
Organ Evaluation and Treatment Relevance
A confirmed GLA result can affect treatment, but the genetic report does not prescribe one therapy for everyone. Care depends on age, sex, phenotype, organ involvement, kidney function, treatment availability, and the specific variant.
Disease-specific options include enzyme replacement therapy and, for eligible people with an amenable variant, the oral pharmacologic chaperone migalastat. Available enzyme products and approved age ranges differ among countries. Supportive treatment remains essential for proteinuria, hypertension, arrhythmia, heart failure, stroke risk, pain, gastrointestinal symptoms, hearing loss, and kidney failure.
Migalastat works by stabilizing certain misfolded forms of alpha-galactosidase A so the enzyme can reach the lysosome and function. It does not work for every GLA variant. Amenability should be established using an accepted laboratory assay and current regional prescribing information; it should not be guessed merely because the variant is missense. A variant described as amenable does not guarantee an equal clinical response in every person.
Enzyme replacement provides functional enzyme through intravenous infusion. Treatment decisions are best made before irreversible fibrosis or organ loss becomes advanced, but timing is individualized. A person with a pathogenic variant and no obvious symptoms may still need close surveillance because silent kidney albumin loss, cardiac changes, or rhythm disease can precede major symptoms.
Genetic findings also help avoid treatment based on a false diagnosis. Lifelong disease-specific therapy is burdensome and expensive. When a GLA VUS is found during screening for hypertrophic cardiomyopathy or kidney disease, clinicians should establish whether Fabry disease is truly present before attributing all organ findings to it.
Monitoring usually follows several domains rather than one marker. A stable lyso-Gb3 value cannot replace urine protein, kidney function, cardiac imaging, rhythm assessment, neurologic review, hearing testing, pain history, and quality-of-life evaluation. Likewise, worsening organ disease may have causes in addition to Fabry disease and should be investigated on its own merits.
Urgent evaluation is needed for stroke-like weakness, facial droop, speech difficulty, sudden severe imbalance, fainting, severe chest pain, sustained rapid or irregular heartbeat with symptoms, or major shortness of breath. Fabry disease can increase cardiovascular and cerebrovascular risk, but emergency teams must also evaluate common causes.
X-Linked Inheritance and Family Testing
GLA lies on the X chromosome, so Fabry disease follows X-linked inheritance.
A male with a pathogenic GLA variant passes his X chromosome to all daughters and his Y chromosome to all sons. Therefore:
- All biological daughters inherit the GLA variant.
- No biological sons inherit the variant from him.
A heterozygous female has a 50% chance of passing the variant in each pregnancy. A child of any sex who inherits it may develop Fabry manifestations. The probability resets with each pregnancy.
Once a familial variant is known, cascade testing can identify relatives before irreversible organ injury develops. Testing should follow the family tree through both male and female relatives. Stopping after testing only men misses heterozygous females who may need care and who can transmit the variant.
Targeted genetic testing is preferred for females because enzyme activity can be normal. For at-risk males, either targeted testing or enzyme analysis may help, but direct testing for the known family variant provides the clearest answer.
A newly diagnosed person can reveal risk across several generations. A genetics professional may construct a three-generation pedigree and identify relatives on the maternal or paternal side depending on who carries the variant. Relatives should receive the exact laboratory report rather than a handwritten gene name, because variant spelling and classification are important.
Reproductive options are available once the familial variant is known. These may include natural conception with or without prenatal diagnosis, chorionic villus sampling, amniocentesis, in vitro fertilization with preimplantation genetic testing for a monogenic condition, donor egg or sperm, donor embryo, adoption, or choosing not to pursue pregnancy.
Prenatal testing can determine whether the fetus inherited the familial variant, but it usually cannot predict the exact age of onset or severity, especially in a female fetus. Reproductive counseling should be nondirective and should include the variable phenotype, the health of the pregnant person, testing limitations, and local availability of services.
Unresolved Results and Next Steps
When the result is unclear, the first step is to verify what was actually tested. A negative report may reflect sequence analysis alone, while deletion-and-duplication analysis was never completed. A broad exome result may have incomplete coverage of GLA or may not have been designed to evaluate certain intronic or structural changes.
A structured review can address the uncertainty:
- Confirm the exact GLA variant, transcript, classification, and testing laboratory.
- Review alpha-galactosidase A activity using an appropriate specimen and method.
- Measure lyso-Gb3 while recognizing its limitations in females and late-onset disease.
- Document Fabry-specific features and objective kidney, cardiac, neurologic, eye, skin, hearing, and pain findings.
- Test informative relatives when segregation could clarify the variant.
- Ask whether deletion-and-duplication, RNA, or another specialized analysis is justified.
- Request periodic variant re-evaluation, particularly when new family or clinical evidence appears.
Alternative diagnoses should remain open. Hypertrophic cardiomyopathy can arise from sarcomere genes, amyloidosis, hypertension, or other metabolic conditions. Kidney disease, small-fiber neuropathy, stroke, angiokeratomas, and gastrointestinal symptoms also have many causes. A negative or uncertain GLA result should prompt a broader differential rather than a forced Fabry label.
Keep the full report, enzyme values, biomarker results, and specialist assessments together. Laboratory reference ranges and methods matter, so a portal message saying “enzyme low” or “gene positive” is not enough for future care.
Questions to ask after testing include:
- Is the variant pathogenic, likely pathogenic, uncertain, or disputed?
- Does the enzyme result fit my sex and the suspected phenotype?
- Was lyso-Gb3 measured, and could a normal value still occur in my situation?
- Did the laboratory perform deletion-and-duplication analysis?
- Is this variant recognized as migalastat-amenable under current regional criteria?
- Which organs need baseline evaluation now?
- Which relatives should receive targeted genetic testing?
- When should the variant classification be reviewed again?
Fabry testing is most valuable when it leads to a coherent diagnosis, a personalized organ assessment, and informed family care. The gene result opens the investigation; it does not replace the clinical work needed to understand how the condition affects one person.
References
- Fabry Disease 2024 (Clinical Review)
- 2024 Update of the TSOC Expert Consensus of Fabry Disease 2024 (Consensus Statement)
- The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review 2025 (Systematic Review)
- Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards 2025 (Expert Review)
- A review and recommendations for oral chaperone therapy in adult patients with Fabry disease 2024 (Position Statement)
- Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations 2023 (Review)
Disclaimer
This article provides general educational information and does not diagnose Fabry disease or replace care from a metabolic specialist, geneticist, cardiologist, nephrologist, neurologist, or genetic counselor. GLA variants, enzyme activity, lyso-Gb3, symptoms, and organ findings must be interpreted together. Seek urgent medical care for possible stroke symptoms, fainting, severe chest pain, sustained symptomatic palpitations, or major breathing difficulty.
